Novelty

The cardiorenal syndrome forms a major socio-economic problem and current diagnostic and therapeutic possibilities are limited. Until now, specific deficits have failed to address the requirements to combat the cardiorenal syndrome. The strength of CaReSyAn is its effort combining all aspects of disease research, starting from identifying disease biomarkers over disease modelling to providing mechanistic insight and developing novel therapy and diagnosis methods.

Further, CaReSyAn will provide mechanistic, technological and complementary training on all aspects above. Altogether, this will enable the generation of multidisciplinary researchers skilled to combat complex diseases and successfully build bridges between clinicians, researchers and companies. Ultimately, this will increase the socio-economic benefit for society and industry.